BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32334833)

  • 1. JAK2 inhibition in JAK2
    Dahlström J; Xia C; Xing X; Yuan X; Björkholm M; Xu D
    Biochem Biophys Res Commun; 2020 Jun; 527(2):425-431. PubMed ID: 32334833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
    Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 study of the Janus kinase 2 (JAK2)
    Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
    Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
    PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.
    Ma L; Clayton JR; Walgren RA; Zhao B; Evans RJ; Smith MC; Heinz-Taheny KM; Kreklau EL; Bloem L; Pitou C; Shen W; Strelow JM; Halstead C; Rempala ME; Parthasarathy S; Gillig JR; Heinz LJ; Pei H; Wang Y; Stancato LF; Dowless MS; Iversen PW; Burkholder TP
    Blood Cancer J; 2013 Apr; 3(4):e109. PubMed ID: 23584399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
    Brkic S; Stivala S; Santopolo A; Szybinski J; Jungius S; Passweg JR; Tsakiris D; Dirnhofer S; Hutter G; Leonards K; Lischer HEL; Dettmer MS; Neel BG; Levine RL; Meyer SC
    Leukemia; 2021 Oct; 35(10):2875-2884. PubMed ID: 34480104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
    de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
    Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+ /CD38- cells and sensitizes them to antileukemia agents.
    Ikezoe T; Yang J; Nishioka C; Kojima S; Takeuchi A; Phillip Koeffler H; Yokoyama A
    Int J Cancer; 2011 May; 128(10):2317-25. PubMed ID: 21128225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
    Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
    Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells.
    Machado-Neto JA; de Melo Campos P; Favaro P; Lazarini M; da Silva Santos Duarte A; Lorand-Metze I; Costa FF; Saad ST; Traina F
    Oncotarget; 2015 Oct; 6(30):29573-84. PubMed ID: 26356819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].
    Liu GM; Zhang LJ; Fu JZ; Liang WT; Cheng ZY; Bai P; Bian YS; Wan JS
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):140-145. PubMed ID: 28279039
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting glutamine metabolism in myeloproliferative neoplasms.
    Zhan H; Ciano K; Dong K; Zucker S
    Blood Cells Mol Dis; 2015 Oct; 55(3):241-7. PubMed ID: 26227854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
    Pandey G; Mazzacurati L; Rowsell TM; Horvat NP; Amin NE; Zhang G; Akuffo AA; Colin-Leitzinger CM; Haura EB; Kuykendall AT; Zhang L; Epling-Burnette PK; Reuther GW
    Am J Hematol; 2024 Jun; 99(6):1040-1055. PubMed ID: 38440831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
    Mazzacurati L; Collins RJ; Pandey G; Lambert-Showers QT; Amin NE; Zhang L; Stubbs MC; Epling-Burnette PK; Koblish HK; Reuther GW
    Blood Adv; 2019 Nov; 3(22):3503-3514. PubMed ID: 31725895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].
    Zhao YL; Zhang LJ; Fu JZ; Xu Q; Liu GM; Xie XL; Liang WT; Cheng ZY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Jul; 47(4):473-478. PubMed ID: 28591945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.